The association between the benefits of metabolic surgery and increased secretion of gut hormones such as glucagon-like peptide (GLP)-1 has led to the development of a class of drugs active in both obesity and T2D. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.